NCT06852963View on ClinicalTrials.gov

A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

August 1, 2027

Conditions
Retinitis Pigmentosa 11Retinal DegenerationRetinal DiseaseEye Diseases HereditaryRetinal Dystrophies
Interventions
DRUG

VP-001

VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.

Trial Locations (6)

32209

University of Florida College of Medicine, Jacksonville

33136

Bascom Palmer Eye Institute - University of Miami, Miami

48105

Kellogg Eye Center - University of Michigan, Ann Arbor

75231

Retina Foundation of the Southwest, Dallas

77030

Baylor College of Medicine, Houston

97239

Casey Eye Institute - OHSU, Portland

Sponsors

Lead Sponsor

PYC Therapeutics
All Listed Sponsors
lead

PYC Therapeutics

INDUSTRY

NCT06852963 - A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001 | Biotech Hunter | Biotech Hunter